![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
, I am starting to miss your 'mega' picks a bit 
Petroleo Brasileiro SA Petrobras
PBR
Strategy
MSTR
NVIDIA
NVDA
Vale SA
VALE
KB Home
KBH
US Stock MarketDetailed Quotes
RANI Rani Therapeutics
- 1.850
- +0.010+0.54%
Close Feb 14 16:00 ET
- 1.860
- +0.010+0.54%
Post 20:01 ET
61.63MMarket Cap-1.76P/E (TTM)
1.900High1.760Low667.14KVolume1.870Open1.840Pre Close1.23MTurnover3.19%Turnover RatioLossP/E (Static)33.31MShares8.75052wk High19.68P/B38.68MFloat Cap1.24052wk Low--Dividend TTM20.91MShs Float36.270Historical High--Div YieldTTM7.62%Amplitude1.240Historical Low1.836Avg Price1Lot Size
Rani Therapeutics Stock Forum
Sign in to post a comment
$Rani Therapeutics (RANI.US)$ when will it go up
1
2
$Rani Therapeutics (RANI.US)$ 1.22 Then 6+ watch.
1
3
$Rani Therapeutics (RANI.US)$ they will be adding 3mill shares to this float but enjoy the pump as you can, CPIX going 5 to 8 maybe 10+
2
2
$Rani Therapeutics (RANI.US)$ wait for post market
1
2
$Rani Therapeutics (RANI.US)$
The preclinical results for Rani's oral semaglutide delivery system represent a potentially significant advancement in the $3.1 billion GLP-1 obesity market. The data reveals three critical technical achievements:
Exceptional bioavailability of 107% compared to subcutaneous injection - notably superior to traditional oral peptide delivery systems which typically achieve only single-digit bioavailability
Matching pharmacokinetic profiles (Cm...
The preclinical results for Rani's oral semaglutide delivery system represent a potentially significant advancement in the $3.1 billion GLP-1 obesity market. The data reveals three critical technical achievements:
Exceptional bioavailability of 107% compared to subcutaneous injection - notably superior to traditional oral peptide delivery systems which typically achieve only single-digit bioavailability
Matching pharmacokinetic profiles (Cm...
4
5
NOTE!
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, ...
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, ...
56
13
1
$Rani Therapeutics (RANI.US)$
Oral Wegovy Alternative Shows Breakthrough Results: Rani's Pill Matches Injectable Efficacy
Oral Wegovy Alternative Shows Breakthrough Results: Rani's Pill Matches Injectable Efficacy
No comment yet
Trending Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
老板画的饼 : Bought the dip, wait, nobody knows.
GirlintheCorner : might be today.